FGC
ALXN

Financial Gravity Companies’s Alexion Pharmaceuticals ALXN Stock Holding History

Financial Gravity Companies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$196K Buy
+1,551
New +$183K 0.18% 133
2018
Q1 		$211K Buy
1,845
+1,113
+152% +$133K 0.22% 85
2017
Q4 		$87K Buy
+732
New +$89.1K 0.1% 202

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Financial Gravity Companies's ALXN Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2018: 1,551 shares worth $196K. The stake represents 0.18% of the portfolio and ranks #133 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in ALXN as recently as Q1 2018.

Financial Gravity Companies first reported a position in ALXN in Q4 2017 and has held it in 3 quarters since. The position peaked at $211K in Q1 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Financial Gravity Companies held 1,551 shares of Alexion Pharmaceuticals worth $196K as of Q4 2018.
  • Alexion Pharmaceuticals was a new Financial Gravity Companies position in Q4 2018.
  • Alexion Pharmaceuticals made up 0.18% of Financial Gravity Companies's portfolio in Q4 2018, its #133 holding.
  • Financial Gravity Companies first reported a position in Alexion Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • Financial Gravity Companies's Alexion Pharmaceuticals position peaked at $211K in Q1 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.